{"protocolSection":{"identificationModule":{"nctId":"NCT03147053","orgStudyIdInfo":{"id":"XiyuanH"},"organization":{"fullName":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","class":"OTHER"},"briefTitle":"Efficacy and Safety of Jiedu Tongluo Granules for Post-stroke Depression","officialTitle":"The Efficacy and Safety of Jiedu Tongluo Granules on Patients With Post-stroke Depression: a Double-blind, Randomized and Placebo-controlled Trial"},"statusModule":{"statusVerifiedDate":"2017-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-04-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-07-07","type":"ACTUAL"},"completionDateStruct":{"date":"2018-01-24","type":"ACTUAL"},"studyFirstSubmitDate":"2017-05-01","studyFirstSubmitQcDate":"2017-05-09","studyFirstPostDateStruct":{"date":"2017-05-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-08-20","lastUpdatePostDateStruct":{"date":"2019-08-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To explore the efficacy and safety of Jiedu Tongluo granules for post stroke depression. A randomized, double-blind, placebo-controlled clinical trial was designed. The treatment group was administered the Jiedu Tongluo granules, while the control group was administered the placebo."},"conditionsModule":{"conditions":["Post-stroke Depression"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":55,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Jiedu Tongluo granules","type":"EXPERIMENTAL","description":"Patients in this group were administered the Jiedu Tongluo granules .","interventionNames":["Drug: Jiedu Tongluo granules"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Patients in this group were administered the placebo .","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Jiedu Tongluo granules","description":"Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.","armGroupLabels":["Jiedu Tongluo granules"],"otherNames":["The treatment group"]},{"type":"DRUG","name":"Placebo","description":"Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.","armGroupLabels":["Placebo"],"otherNames":["The control group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change of 17-item Hamilton Depression Scale( HAMD-17) From Baseline","description":"Depression symptoms are mainly measured by the 17-item Hamilton Depression Scale (HAMD-17)","timeFrame":"4weeks,8weeks"},{"measure":"Change of Barthel Index (BI) From Baseline","description":"The daily activities will be measured using Barthel Index(BI)","timeFrame":"4weeks,8weeks"}],"secondaryOutcomes":[{"measure":"Change of National Institute of Health stroke scale（NIHSS）From Baseline","description":"Neurological function mainly measured by NIHSS","timeFrame":"4weeks,8weeks"},{"measure":"The stroke diagnosis and evaluation criteria of Traditional Chinese Medicine（TCM）from baseline","description":"To evaluate patients' syndrome by TCM scale","timeFrame":"4weeks,8weeks"}],"otherOutcomes":[{"measure":"The change of cytokines IL-6、 IL-8 in serum from baseline","description":"To find the inflammation factors related with post-stroke depression","timeFrame":"4weeks,8weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of stroke, with neurological deficits symptoms;\n* Clinical diagnosis of depression, according to the Diagnostic and Statistical Manual of Mental Disorders-IV （DSM-IV）or Chinese Classification and Diagnostic Criteria of Mental Disorders-3(CCMD-3), the score is between 7 to 24 by 17-item Hamilton Depression;\n* Age of 45 to 80 years old;\n* The patient is conscious, cooperation, without aphasia and severe cognitive impairment after acute phase of stroke;\n* Without psychiatric disease history or family history of psychosis before stroke;\n* No hormones and psychotropic drugs were used within 1 month before enrollment;\n* capacity to provide written consent.\n\nExclusion Criteria:\n\n* With brain organic disease such as brain tumors;\n* Had a history of psychiatric illness or depression before stroke;\n* Combined with severe liver, kidney, hematopoietic system disorder;\n* Poor glycemic control and insulin-dependent diabetes;\n* Participate in any clinical trial or taking antidepressant treatment 1 month prior to baseline;\n* Pregnant or breast feeding;\n* History of sensitivity to Chinese medicine ingredients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Jianxun Liu","affiliation":"xiyuan hospital","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}}]},"referencesModule":{"references":[{"pmid":"29747670","type":"DERIVED","citation":"Zhao AM, Qiu WR, Mao LJ, Ren JG, Xu L, Yao MJ, Bilinksi K, Chang D, Liu JX. The efficacy and safety of Jiedu Tongluo granules for treating post-stroke depression with qi deficiency and blood stasis syndrome: study protocol for a randomized controlled trial. Trials. 2018 May 10;19(1):275. doi: 10.1186/s13063-018-2633-4."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000003863","term":"Depression"},{"id":"D000003866","term":"Depressive Disorder"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001526","term":"Behavioral Symptoms"},{"id":"D000019964","term":"Mood Disorders"},{"id":"D000001523","term":"Mental Disorders"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M6748","name":"Depression","asFound":"Depression","relevance":"HIGH"},{"id":"M6751","name":"Depressive Disorder","asFound":"Depression","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4508","name":"Behavioral Symptoms","relevance":"LOW"},{"id":"M21525","name":"Mood Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]}},"hasResults":false}